KEY FINDINGS The Asia-Pacific IBS-c drug market is predicted to grow at a CAGR of 6.29% over the forecast period of 2017-2025 and generate an estimated revenue of $210.28 million by the end of 2025. The high unmet needs for the drugs in the Asian region leading to a subsequent higher demand from the market are expected to boost the market growth in the coming years
MARKET INSIGHTS IBS being a heritable condition in some of the population, the poor and unhealthy eating habits and the pipeline drugs in the market are some of the major drivers for the Asian IBS-c drug market. The market is segmented according to the prescription type and drug type. The prescription type is further classified into over the counter drugs and prescription drugs, with the over the counter drugs being more popular in the market. The drug type segment contains Stimulant Laxatives, Osmotic Laxatives, Lubiprostone, Linaclotide, and some pipeline drugs such as plecanatide. Of these, lubiprostone currently has the highest market share in the market. However, the change in lifestyle and the use of alternate natural ways to cure IBS might prove challenging for the market in the future. COMPETITIVE INSIGHTS Some of the major companies in the region are Prometheus Laboratories Inc, Norgine B.V, Actavis Nordic A/S, Yuhan Corp, Albireo Pharma Inc, Astrazeneca Plc, The Menarini Group and Ono Pharmaceutical Co., Ltd.